Skip to main content

Advertisement

SpringerLink
Log in

The Third Consensus Conference on the treatment of aplastic anemia

  • Meeting Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;105:2509–19.

    Article  Google Scholar 

  2. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathopysiology and treatment. Biol Blood Marrow Transplant. 2010;16:S119–25.

    Article  PubMed  Google Scholar 

  3. Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anemia: a long-term follow-up. Br J Haematol. 2005;130:747–51.

    Article  CAS  PubMed  Google Scholar 

  4. Yagasaki H, Takahashi Y, Hama A, Kudo K, Nishio N, Muramatsu H, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant. 2010 Feb 1 [Epub ahead of print].

  5. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348–53.

    CAS  PubMed  Google Scholar 

  6. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.

    CAS  PubMed  Google Scholar 

  7. Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4.

    Article  PubMed  Google Scholar 

  8. Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208–15.

    Article  CAS  PubMed  Google Scholar 

  9. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803.

    Article  CAS  PubMed  Google Scholar 

  10. Maury S, Balère-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92:589–96.

    Article  PubMed  Google Scholar 

  11. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O’Connor KC, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102:4567–75.

    Article  CAS  PubMed  Google Scholar 

  12. Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, et al. Clinical impact of HLA DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anemia. Br J Haematol. 2008;142:427–35.

    Article  CAS  PubMed  Google Scholar 

  13. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–14.

    Article  CAS  PubMed  Google Scholar 

  14. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112:965–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–92.

    CAS  PubMed  Google Scholar 

  16. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110:1439–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362:1628–30.

    Article  CAS  PubMed  Google Scholar 

  18. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413–24.

    Article  CAS  PubMed  Google Scholar 

  19. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.

    Article  CAS  PubMed  Google Scholar 

  21. Passweg JR, Pérez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37:641–9.

    Article  CAS  PubMed  Google Scholar 

  22. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–50.

    Article  CAS  PubMed  Google Scholar 

  23. Deeg HJ, O’Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, et al. Tacrolimus/methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant. 2009;15:1603–8.

    Article  CAS  PubMed  Google Scholar 

  25. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690–7.

    CAS  PubMed  Google Scholar 

  27. Bacigalupo A, Socie’ G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation for alternative donor transplants in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95:976–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Deeg HJ, Socié G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–92.

    CAS  PubMed  Google Scholar 

  29. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107:330–4.

    Article  CAS  PubMed  Google Scholar 

  30. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009;23:1297–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115:2136–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tisdale JF, Dunn DE, Geller N, Plante M, Nunez O, Dunbar CE, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356:1554–9.

    Article  CAS  PubMed  Google Scholar 

  34. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119:1075–82.

    Article  CAS  PubMed  Google Scholar 

  35. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007;110:1756–61.

    Article  CAS  PubMed  Google Scholar 

  36. Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Daehrsen U, et al. Use of G-CSF in patients with severe aplastic anemia treatment with ATG and cyclosporine increases neutrophils and decreases infection rates and hospital days but dose not improve long-term outcome: Results of a prospective randomizes clinical trial of the EBMT. Blood. 2009;114:205a.

    Google Scholar 

  37. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010 Jun 21 [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Nagoya University, Nagoya, Japan

    Seiji Kojima, Shinji Nakao, Neal Young, Andrea Bacigalupo, Gerard Gerard, Naoto Hirano, Jaroslaw Maciejewski, Joachim Deeg, Judith Marsh, Feng-Kui Zhang, Jong Wook Lee & Keiya Ozawa

Authors
  1. Seiji Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinji Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerard Gerard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoto Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jaroslaw Maciejewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joachim Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Feng-Kui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jong Wook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keiya Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seiji Kojima.

Appendix

Appendix

The following persons participated in the conference

Hoon Kook (Gwangiu, Korea), Dae Chul Jeong (Seoul, Korea), Jong Wook Lee (Seoul, Korea), Surapol Issaragagrisil (Bankok,Thailand), Xiao-Fan Zhu (Tianjin, China), Feng-Kui Zhang (Tianjin, China), Jing-Yan Tang (Shanghai, China), Jianping Shen (Hangzhou, China), Minghui Duan (Beijing, China), Jun Ma (Harbin, China), Honorata Baylon (Manila, Philippine), See Voon Seow (Singapore), Michelle Poon (Singapore), Lily Wong Lee (Sabah, Malaysia), Naoto Hirano (Boston, USA), Jaroslaw Maciejewski (Cleveland, USA), Neal Young (Bethesda, USA), Joachim Deeg (Seattle, USA), Andrea Bacigalupo (Genova, Italy), Judith Marsh (London, UK), Gerard Socie (Paris, France), Keiya Ozawa (Tochigi, Japan), Masao Tomonaga (Nagasaki, Japan), Shinji Nakao (Kanazawa, Japan), Hiroto Yamazaki (Kanazawa, Japan), Akio Urabe (Tokyo, Japan), Seishi Ogawa (Tokyo, Japan), Hiroki Yamaguchi (Tokyo, Japan), Masanao Teramura (Tokyo, Japan), Kensuke Usuki (Tokyo, Japan), Chitose Ogawa (Tokyo, Japan), Ohara Akira (Tokyo, Japan), Tatsutoshi Nakahata (Kyoto, Japan), Hiromasa Yabe (Isehara, Japan), Etsuro Ito (Hirosaki, Japan), Kazuko Kudo (Shizuoka, Japan), Seiji Kojima (Nagoya, Japan), Yoshiyuki Takahashi (Nagoya, Japan), Haruhiko Ohashi (Nagoya, Japan), Koichi Miyamura (Nagoya, Japan).

About this article

Cite this article

Kojima, S., Nakao, S., Young, N. et al. The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol 93, 832–837 (2011). https://doi.org/10.1007/s12185-011-0873-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-011-0873-0

Keywords

Search

Navigation